Jian-Jun Chu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jian-Jun Chu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Yang Xu
School of Food and Biological Engineering, Hefei University of Technology, Hefei, China
9 shared publications Lu-Yang Han
Bengbu Medical University, The Second People's Hospital of Hefei (Affiliated Hospital), Anhui 230011, China
8 shared publicationsLong-Xu Han
The Second People's Hospital of Hefei, Anhui Medical University, Hefei, China
6 shared publicationsWen-Han Bu
Bengbu Medical University, The Second People's Hospital of Hefei (Affiliated Hospital), Anhui 230011, China
6 shared publicationsYin-Yu Qi
Department of Orthopedics, Second People's Hospital of Hefei, Hefei, Hefei, Anhui, 230011, CHINA
5 shared publicationsZhe Gao
Department of Orthopedics, The Second People's Hospital of Hefei, Hefei, Hefei, 230011, CHINA
5 shared publications
Latest Publications
- Open Access
- 16 January 2026
- Published by Elsevier in Bone Reports
- Vol. 28, 101898
Intelligent identification of osteoporosis on hip X-rays using vision transformer
- 16 January 2026
- Published by Elsevier in Bone Reports
- Vol. 28, 101898
Open AccessIntelligent identification of osteoporosis on hip X-rays using vision transformer
- Open Access
- 12 December 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1071
Targeting macrophage JAK3/STAT3 signaling with tectochrysin: a novel therapeutic strategy to ameliorate bone erosion and synovitis in rheumatoid arthritis
This study aims to clarify whether Tectochrysin has a therapeutic effect on rheumatoid arthritis animal models and to explore the potential therapeutic mec
- 12 December 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1071
Open AccessTargeting macrophage JAK3/STAT3 signaling with tectochrysin: a novel therapeutic strategy to ameliorate bone erosion and synovitis in rheumatoid arthritis
This study aims to clarify whether Tectochrysin has a therapeutic effect on rheumatoid arthritis animal models and to explore the potential therapeutic mec
- Open Access
- 1 November 2025
- Published by IOP Publishing in Biomedical Materials
- Vol. 20 (6) , 065027
Composite bone cements based on halloysite nanotube with enhanced drug elution
Antibiotic-loaded PMMA (polymethylmethacrylate) bone cement (ALBC) is widely used to prevent and treat periprosthetic joint infections (PJIs), yet its clinical efficacy is limited by issues like burst release and short release duration. To address these challenges, this study developed a composite bone cement (HV-PMMA) loaded with vancomycin-functionalized halloysite nanotubes (HNTs-Van). The results showed that HV-PMMA optimized antibiotic elution: it avoided initial burst release, and the drug elution amount of HV-PMMA was superior to that of traditional ALBC with vancomycin formulation. The addition of HNTs-Van slightly reduces the compressive strength of the bone cement. Importantly, HV-PMMA maintained good biocompatibility, with a hemolysis rate below 5% and no acute systemic toxicity. This nano-scale physical drug-loading strategy effectively solves the limitations of traditional ALBC, providing an efficient and safe approach for designing antibacterial bone cements to prevent and treat PJIs.
- 1 November 2025
- Published by IOP Publishing in Biomedical Materials
- Vol. 20 (6) , 065027
Open AccessComposite bone cements based on halloysite nanotube with enhanced drug elution
Antibiotic-loaded PMMA (polymethylmethacrylate) bone cement (ALBC) is widely used to prevent and treat periprosthetic joint infections (PJIs), yet its clinical efficacy is limited by issues like burst release and short release duration. To address these challenges, this study developed a composite bone cement (HV-PMMA) loaded with vancomycin-functionalized halloysite nanotubes (HNTs-Van). The results showed that HV-PMMA optimized antibiotic elution: it avoided initial burst release, and the drug elution amount of HV-PMMA was superior to that of traditional ALBC with vancomycin formulation. The addition of HNTs-Van slightly reduces the compressive strength of the bone cement. Importantly, HV-PMMA maintained good biocompatibility, with a hemolysis rate below 5% and no acute systemic toxicity. This nano-scale physical drug-loading strategy effectively solves the limitations of traditional ALBC, providing an efficient and safe approach for designing antibacterial bone cements to prevent and treat PJIs.
- Open Access
- 7 October 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35, 102388
Point-of-care bone cement based on natural peptide comonomer protects orthopaedic implants from bacterial challenge
- 7 October 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35, 102388
Open AccessPoint-of-care bone cement based on natural peptide comonomer protects orthopaedic implants from bacterial challenge
- Open Access
- 17 September 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (41) , 33966-33975
Formulation and characterization of a sortase a inhibitor-loaded PMMA bone cement
A sortase A inhibitor (SrtA I)-loaded bone cement (SLBC) containing 1-(3,4-dichlorophenyl)-3-(dimethylamino)propyl-1-one hydrochloride (AEEK1) was reported. Compared with gentamicin-loaded bone cement (GS cement), which is a widely used antibiotic-loaded bone cement in cemented total joint replacement (TJR), SLBC demonstrated a significantly prolonged effective antibacterial duration against both Staphylococcus aureus (S. aureus) and methicillin-resistant S. aureus (MRSA). The quasi-static compressive strength, maximum polymerization temperature, and setting time of SLBC were within the limits stated in the ISO 5833 standard and comparable to the corresponding values of GS cement. In vitro and in vivo experimental results confirmed the biocompatibility of SLBC and showed its easy injectability into porcine T12 vertebrae. Taken together, these findings suggest that SLBC may have potential for managing/treating prosthetic joint infections, which is a common complication in cemented TJR.
- 17 September 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (41) , 33966-33975
Open AccessFormulation and characterization of a sortase a inhibitor-loaded PMMA bone cement
A sortase A inhibitor (SrtA I)-loaded bone cement (SLBC) containing 1-(3,4-dichlorophenyl)-3-(dimethylamino)propyl-1-one hydrochloride (AEEK1) was reported. Compared with gentamicin-loaded bone cement (GS cement), which is a widely used antibiotic-loaded bone cement in cemented total joint replacement (TJR), SLBC demonstrated a significantly prolonged effective antibacterial duration against both Staphylococcus aureus (S. aureus) and methicillin-resistant S. aureus (MRSA). The quasi-static compressive strength, maximum polymerization temperature, and setting time of SLBC were within the limits stated in the ISO 5833 standard and comparable to the corresponding values of GS cement. In vitro and in vivo experimental results confirmed the biocompatibility of SLBC and showed its easy injectability into porcine T12 vertebrae. Taken together, these findings suggest that SLBC may have potential for managing/treating prosthetic joint infections, which is a common complication in cemented TJR.
- Open Access
- 5 August 2025
- Published by Royal Society of Chemistry (RSC) in Materials Advances
Furanone-based Comonomer Used to Manufacture Antibacterial Bone Cement with Simultaneously Enhanced Mechanical Strength and Antibacterial Activity
A furanone-based methacrylate carbamate comonomer has been reported, which we named FUMA. With this comonomer in hand, a new type of FUMA bone cement was manufactured. Surprisingly, the mechanical strength of the FUMA cement increased with the monomer content, meeting the ISO 5833 requirements. Further studies showed that, the antibacterial activity of the FUMA cement increased with higher monomer content, and the 25% FUMA cement exhibited 97.57 ± 2.27% antibacterial activity against Staphylococcus aureus and 43 ± 4.82% against methicillin-resistant Staphylococcus aureus (MRSA). This cement demonstrated no hemolytic activity or acute toxicity. These findings provide new potential approaches for the prevention of periprosthetic joint infections (PJIs).
- 5 August 2025
- Published by Royal Society of Chemistry (RSC) in Materials Advances
Open AccessFuranone-based Comonomer Used to Manufacture Antibacterial Bone Cement with Simultaneously Enhanced Mechanical Strength and Antibacterial Activity
A furanone-based methacrylate carbamate comonomer has been reported, which we named FUMA. With this comonomer in hand, a new type of FUMA bone cement was manufactured. Surprisingly, the mechanical strength of the FUMA cement increased with the monomer content, meeting the ISO 5833 requirements. Further studies showed that, the antibacterial activity of the FUMA cement increased with higher monomer content, and the 25% FUMA cement exhibited 97.57 ± 2.27% antibacterial activity against Staphylococcus aureus and 43 ± 4.82% against methicillin-resistant Staphylococcus aureus (MRSA). This cement demonstrated no hemolytic activity or acute toxicity. These findings provide new potential approaches for the prevention of periprosthetic joint infections (PJIs).
- Open Access
- 9 January 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (2) , 806-813
Preparation and characterization of novel PMMA bone cement containing 3,4-dichloro-5-hydroxyfuran-2(5 H )-one
A novel antibacterial non-leaching bone cement based 3,4-dichloro-5-hydroxyfuran-2(5 H )-one (DHF) was synthesized. We refer to it as DHF-MAA cement, and it exhibits excellent antibacterial activity, compressive properties, and biocompatibility.
- 9 January 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (2) , 806-813
Open AccessPreparation and characterization of novel PMMA bone cement containing 3,4-dichloro-5-hydroxyfuran-2(5 H )-one
A novel antibacterial non-leaching bone cement based 3,4-dichloro-5-hydroxyfuran-2(5 H )-one (DHF) was synthesized. We refer to it as DHF-MAA cement, and it exhibits excellent antibacterial activity, compressive properties, and biocompatibility.
- 8 January 2025
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 49 (6) , 2106-2115
Bone cement prepared using the isobornyl acrylate monomer shows decent mechanical strength and antibacterial activity
A new type of antibacterial bone cement incorporating surface stereochemistry and the antibacterial monomer isobornyl acrylate (BA) is reported. In this study, BA was integrated into poly(methyl methacrylate) (PMMA) bone cement through liquid-phase modification to create a non-leaching antibacterial bone cement (NLBC). The maximum temperature, setting time, antibacterial activity, mechanical strength, and biocompatibility of this NLBC were comprehensively evaluated. The results showed that the BA cement exhibited exceptional antibacterial activity and mechanical properties. The 30 wt% BA cement demonstrated an antibacterial activity of 81.0 ± 3.1% against Staphylococcus aureus and a compressive strength of 72.10 ± 1.97 MPa. The BA cement exhibited good biocompatibility both in vitro and in vivo. Furthermore, we compared the antibacterial activity, mechanical properties, and biocompatibility of the BA cement with those of three previously reported bone cements, which contain the antibacterial monomers 2-(tert-butylamino)ethyl methacrylate (TBAEMA), methacrylate derived from benzothiazole (BTTMA), and nitrofuran methacrylate (NFMA), respectively. The findings of this study have important implications for the advancement of antibacterial bone cement and its application in medical implants.
- 8 January 2025
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 49 (6) , 2106-2115
Bone cement prepared using the isobornyl acrylate monomer shows decent mechanical strength and antibacterial activity
A new type of antibacterial bone cement incorporating surface stereochemistry and the antibacterial monomer isobornyl acrylate (BA) is reported. In this study, BA was integrated into poly(methyl methacrylate) (PMMA) bone cement through liquid-phase modification to create a non-leaching antibacterial bone cement (NLBC). The maximum temperature, setting time, antibacterial activity, mechanical strength, and biocompatibility of this NLBC were comprehensively evaluated. The results showed that the BA cement exhibited exceptional antibacterial activity and mechanical properties. The 30 wt% BA cement demonstrated an antibacterial activity of 81.0 ± 3.1% against Staphylococcus aureus and a compressive strength of 72.10 ± 1.97 MPa. The BA cement exhibited good biocompatibility both in vitro and in vivo. Furthermore, we compared the antibacterial activity, mechanical properties, and biocompatibility of the BA cement with those of three previously reported bone cements, which contain the antibacterial monomers 2-(tert-butylamino)ethyl methacrylate (TBAEMA), methacrylate derived from benzothiazole (BTTMA), and nitrofuran methacrylate (NFMA), respectively. The findings of this study have important implications for the advancement of antibacterial bone cement and its application in medical implants.
- Open Access
- 3 October 2024
- Published by Frontiers Media SA in Frontiers in Materials
- Vol. 11, 1432482
Antibacterial bone cement modified by long-chain nitrofuran methacrylate using liquid-phase modification strategy
A novel acrylic monomer containing a nitrofuran motif, referred to as long-chain nitrofuran methacrylate (LNFMA), is reported. In comparison to the previously reported nitrofuran methacrylate (NFMA), LNFMA has a longer side chain, and when incorporated into bone cement, the resulting LNFMA bone cement exhibits improved mechanical strength. At the same concentration, NFMA-5% cement has only 21.6 ± 1.3 MPa, while LNFMA-5% cement has a compressive strength of 42.64 ± 0.94 MPa. LNFMA bone cements exhibit antimicrobial activity against Staphylococcus aureus, with LNFMA-30% cement reaching 57.38% ± 5.53%. Moreover, LNFMA cement demonstrates excellent biocompatibility both in vitro and in vivo. The results showed that LNFMA monomer had optimized mechanical strength compared with previously reported NFMA monomers, and LNFMA bone cement had good antibacterial activity and biocompatibility.
- 3 October 2024
- Published by Frontiers Media SA in Frontiers in Materials
- Vol. 11, 1432482
Open AccessAntibacterial bone cement modified by long-chain nitrofuran methacrylate using liquid-phase modification strategy
A novel acrylic monomer containing a nitrofuran motif, referred to as long-chain nitrofuran methacrylate (LNFMA), is reported. In comparison to the previously reported nitrofuran methacrylate (NFMA), LNFMA has a longer side chain, and when incorporated into bone cement, the resulting LNFMA bone cement exhibits improved mechanical strength. At the same concentration, NFMA-5% cement has only 21.6 ± 1.3 MPa, while LNFMA-5% cement has a compressive strength of 42.64 ± 0.94 MPa. LNFMA bone cements exhibit antimicrobial activity against Staphylococcus aureus, with LNFMA-30% cement reaching 57.38% ± 5.53%. Moreover, LNFMA cement demonstrates excellent biocompatibility both in vitro and in vivo. The results showed that LNFMA monomer had optimized mechanical strength compared with previously reported NFMA monomers, and LNFMA bone cement had good antibacterial activity and biocompatibility.
- Open Access
- 28 May 2024
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 12, 1414005
Preparation and efficacy of antibacterial methacrylate monomer-based polymethyl methacrylate bone cement containing N-halamine compounds
Introduction: Our objective in this study was to prepare a novel type of polymethyl methacrylate (PMMA) bone cement, analyze its material properties, and evaluate its safety and antibacterial efficacy.Methods: A halamine compound methacrylate antibacterial PMMA bone cement containing an N-Cl bond structure was formulated, and its material characterization was determined with Fourier transform infrared spectroscopy (FT-IR) and 1H-NMR. The antibacterial properties of the material were studied using contact bacteriostasis and releasing-type bacteriostasis experiments. Finally, in vitro and in vivo biocompatibility experiments were performed to analyze the toxic effects of the material on mice and embryonic osteoblast precursor cells (MC3T3-E1).Results: Incorporation of the antibacterial methacrylate monomer with the N-halamine compound in the new antibacterial PMMA bone cement significantly increased its contact and releasing-type bacteriostatic performance against Staphylococcus aureus. Notably, at 20% and 25% additions of N-halamine compound, the contact and releasing-type bacteriostasis rates of bone cement samples reached 100% (p < 0.001). Furthermore, the new antibacterial bone cement containing 5%, 10%, and 15% N-halamine compounds showed good biocompatibility in vitro and in vivo.Conclusion: In this study, we found that the novel antibacterial PMMA bone cement with N-halamine compound methacrylate demonstrated good contact and releasing-type bacteriostatic properties against S. aureus. In particular, bone cement containing a 15% N-halamine monomer exhibited strong antibacterial properties and good in vitro and in vivo biocompatibility.
- 28 May 2024
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 12, 1414005
Open AccessPreparation and efficacy of antibacterial methacrylate monomer-based polymethyl methacrylate bone cement containing N-halamine compounds
Introduction: Our objective in this study was to prepare a novel type of polymethyl methacrylate (PMMA) bone cement, analyze its material properties, and evaluate its safety and antibacterial efficacy.Methods: A halamine compound methacrylate antibacterial PMMA bone cement containing an N-Cl bond structure was formulated, and its material characterization was determined with Fourier transform infrared spectroscopy (FT-IR) and 1H-NMR. The antibacterial properties of the material were studied using contact bacteriostasis and releasing-type bacteriostasis experiments. Finally, in vitro and in vivo biocompatibility experiments were performed to analyze the toxic effects of the material on mice and embryonic osteoblast precursor cells (MC3T3-E1).Results: Incorporation of the antibacterial methacrylate monomer with the N-halamine compound in the new antibacterial PMMA bone cement significantly increased its contact and releasing-type bacteriostatic performance against Staphylococcus aureus. Notably, at 20% and 25% additions of N-halamine compound, the contact and releasing-type bacteriostasis rates of bone cement samples reached 100% (p < 0.001). Furthermore, the new antibacterial bone cement containing 5%, 10%, and 15% N-halamine compounds showed good biocompatibility in vitro and in vivo.Conclusion: In this study, we found that the novel antibacterial PMMA bone cement with N-halamine compound methacrylate demonstrated good contact and releasing-type bacteriostatic properties against S. aureus. In particular, bone cement containing a 15% N-halamine monomer exhibited strong antibacterial properties and good in vitro and in vivo biocompatibility.